SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 /
$Ainos(AIMD.US)$ ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the second quarter ended June 30, 2022.
Second Quarter 2022 Financial Highlights
Revenues were US$636,627 in the second quarter of 2022, up 213.6% from US$202,992 in the same period of 2021.
Gross profit was US$317,664, representing a gross margin of 49.9% in the second quarter of 2022.
Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We are pleased to announce our first quarterly results as a Nasdaq-listed company with significant year-over-year revenue growth and promising operational milestones. This has been a momentous year for us, our partners, and our shareholders. Receiving approval for our COVID-19 Antigen Self-Test to be sold in Taiwan and the positive preclinical study results for our VELDONA interferon formulation demonstrates the strength of our product portfolio as we strive to fulfill our mission to develop a telehealth-enabled future for precision medicine. Our Nasdaq uplisting is an exciting new chapter in our development, providing us with wider access to capital, raising our corporate profile, and positioning us to deliver greater and more sustainable value for our shareholders. With our low-cost operations and cutting-edge technology, the building blocks for our future growth as a diversified medtech company are firmly in place."
Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "Increased sales of our COVID-19 Antigen Rapid Test Kits during the second quarter drove robust year-over-year 213.6% top-line growth. With the additional capital provided by our recent uplisting, we are well positioned to meet our product development targets, capture emerging market opportunities, and generate long-term growth for our shareholders. Looking ahead, we will continue to commercialize our medical device pipeline while expanding and strengthening our innovative product portfolio."
Second Quarter 2022 Financial Results
Revenues
Revenues increased by 213.6% to US$636,627 in the second quarter of 2022 from US$202,992 in the same period of 2021, mainly driven by the increased product sales of the Ainos COVID-19 Antigen Rapid Test Kits in Taiwan.
Cost of Revenues
Cost of revenues was US$318,963 in the second quarter of 2022, compared with US$69,508 in the same period of 2021, mainly driven by the increase in associated cost of product sales of the Ainos COVID-19 Antigen Rapid Test Kits.
Gross Profit
Gross profit was US$317,664, representing 49.9% of sales in the second quarter of 2022.
Total Operating Expenses
Total operating expenses increased by 163.0% to US$2,261,960 in the second quarter of 2022 from US$860,030 in the same period of 2021, mainly attributable to increased research and development expenses. The increase in research and development expenses reflects the Company's ongoing investments in research and development, in line with its product development plans.
Net Loss
Net loss attributable to common stock shareholders was US$1,954,032 in the second quarter of 2022, compared with US$749,774 in the same period of 2021.
Balance Sheet
As of June 30, 2022, the Company had cash and cash equivalents of US$1,753,877, compared with US$1,751,499 as of December 31, 2021.
Recent Developments
On June 21, 2022, the Company announced it has begun marketing the Ainos COVID-19 Antigen Self-Test Kit under an Emergency Use Authorization that was issued by the Taiwan Food and Drug Administration on June 13, 2022 to Taiwan Carbon Nano Technology Corporation, the manufacturer and product co-developer of the test in conjunction with Ainos. Ainos is the exclusive master sales and marketing agent for the COVID-19 Antigen Self-Test Kit.
On June 27, 2022, the Company announced the topline results from its COVID-19 antiviral efficacy study in hamsters. The available results show that its low-dose oral interferon alpha formulation, VELDONA, has a protective effect on lungs infected with the SARS-CoV-2 virus by regulating the immune response, thus expediting recovery of infected animals. The Company is preparing application documents for U.S. FDA Phase 2/3 clinical trials.
On August 12, 2022, the Company announced the closing of its previously announced underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. The common stock and warrants were immediately separable and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on August 9, 2022, under the symbols "AIMD" and "AIMDW," respectively. Ainos received gross proceeds of approximately $3.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos is committed to developing a comprehensive healthcare business portfolio encompassing medical devices and consumer healthcare products. While prioritizing the commercialization of medical devices as part of its diversification strategy, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. Leveraging its patents related to VOC technologies and three issued patents for COVID-19 POCT products, the Company seeks to expedite the commercialization of its medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," 'target," "future," "seek," "likely," "strategy," "may," "should," "will," and similar references to future periods. Forward-looking statements are based only on our current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the following: the cost of production and sales potential of the planned drug treatments announced in this press release; the impact of final approvals from the U.S. Food and Drug Administration (the "FDA") or other regulatory bodies for the planned drug treatments including the availability of emergency use authorization; the Company's limited cash and history of losses; the Company's ability to achieve profitability; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; the Company's ability to manufacture any products it develops; general economic conditions and events and the impact they may have on the Company and its potential customers, including but not limited to the impact of Covid-19; the Company's ability to obtain adequate financing in the future; the impact of promulgation and implementation of regulations by the World Health Organization, the FDA and by other governmental authorities with functions similar to those of the FDA on the Company's operations and technologies; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; the Company's ability to secure regulatory approvals for its products; and our success in managing the risks involved in the foregoing items. Readers should also review the risks and uncertainties listed in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports we file with the U.S. Securities and Exchange Commission.
Any forward-looking statement made by us in this press release speaks only as of the date on which such statement is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: Ainos.IR@icrinc.com
Ainos, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
|
| Three months ended June 30, |
|
| Six months ended June 30, |
|
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
|
Revenues |
| $ | 636,627 |
|
| $ | 202,992 |
|
| $ | 723,828 |
|
| $ | 205,113 |
|
Cost of revenues |
|
| (318,963 | ) |
|
| (69,508 | ) |
|
| (360,042 | ) |
|
| (70,757 | ) |
Gross profit |
|
| 317,664 |
|
|
| 133,484 |
|
|
| 363,786 |
|
|
| 134,356 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
| 1,634,856 |
|
|
| - |
|
|
| 3,212,310 |
|
|
| - |
|
Selling, general and administrative expenses |
|
| 627,104 |
|
|
| 860,030 |
|
|
| 1,178,834 |
|
|
| 1,383,011 |
|
Total operating expenses |
|
| 2,261,960 |
|
|
| 860,030 |
|
|
| 4,391,144 |
|
|
| 1,383,011 |
|
Operating loss |
|
| (1,944,296 | ) |
|
| (726,546 | ) |
|
| (4,027,358 | ) |
|
| (1,248,655 | ) |
Non-operating income and expenses, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on sale of fixed assets |
|
| - |
|
|
| (2,247 | ) |
|
| - |
|
|
| (2,247 | ) |
Interest expense, net |
|
| (18,796 | ) |
|
| (20,981 | ) |
|
| (35,483 | ) |
|
| (32,879 | ) |
Other income, net |
|
| 9,060 |
|
|
| - |
|
|
| 8,914 |
|
|
| - |
|
Total non-operating income and expenses, net |
|
| (9,736 | ) |
|
| (23,228 | ) |
|
| (26,569 | ) |
|
| (35,126 | ) |
Net loss |
|
| (1,954,032 | ) |
|
| (749,774 | ) |
|
| (4,053,927 | ) |
|
| (1,283,781 | ) |
Basic and diluted net loss per average share available to common shareholders |
| $ | (0.01 | ) |
| $ | (0.01 | ) |
| $ | (0.03 | ) |
| $ | (0.02 | ) |
Weighted average common shares outstanding - basic and diluted |
|
| 144,379,308 |
|
|
| 124,644,759 |
|
|
| 144,379,308 |
|
|
| 83,583,583 |
|
Ainos, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
| June 30, |
|
| December 31, |
|
| 2022 |
|
| 2021 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
| $ | 1,753,877 |
|
| $ | 1,751,499 |
|
Inventory |
|
| 670,507 |
|
|
| - |
|
Other current assets |
|
| 1,274,512 |
|
|
| 466,198 |
|
Total current assets |
|
| 3,698,896 |
|
|
| 2,217,697 |
|
Intangible assets, net |
|
| 35,086,424 |
|
|
| 37,329,191 |
|
Property and equipment, net |
|
| 1,503,025 |
|
|
| 1,187,702 |
|
Other assets |
|
| 124,697 |
|
|
| 87,571 |
|
Total assets |
| $ | 40,413,042 |
|
| $ | 40,822,161 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Convertible notes payable |
| $ | 3,376,526 |
|
| $ | 3,376,526 |
|
Notes payable |
|
| 1,013,405 |
|
|
| 213,405 |
|
Accrued expenses and others current liabilities |
|
| 2,598,468 |
|
|
| 1,004,868 |
|
Payables - related party |
|
| - |
|
|
| 26,000,000 |
|
Total current liabilities |
|
| 6,988,399 |
|
|
| 30,594,799 |
|
Long term liabilities: |
|
|
|
|
|
|
|
|
Convertible notes payable - noncurrent |
|
| 27,400,000 |
|
|
| - |
|
Operating lease liabilities - noncurrent |
|
| 18,323 |
|
|
| 30,255 |
|
Total long term liabilities |
|
| 27,418,323 |
|
|
| 30,255 |
|
Total liabilities |
|
| 34,406,722 |
|
|
| 30,625,054 |
|
Stockholders' equity |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value; 10,000,000 shares |
|
|
|
|
|
|
|
|
authorized; none issued |
|
|
|
|
|
|
|
|
Common stock, $0.01 par value; 300,000,000 shares |
|
|
|
|
|
|
|
|
authorized as of June 30, 2022 and December 31, |
|
|
|
|
|
|
|
|
2021; 144,379,308 shares issued and outstanding as |
|
|
|
|
|
|
|
|
of June 30, 2022 and December 31, 2021 |
|
| 1,443,793 |
|
|
| 1,443,793 |
|
Additional paid-in capital |
|
| 18,943,316 |
|
|
| 18,856,430 |
|
Accumulated deficit |
|
| (14,162,843 | ) |
|
| (10,108,916 | ) |
Translation adjustment |
|
| (217,946 | ) |
|
| 5,800 |
|
Total stockholders' equity |
|
| 6,006,320 |
|
|
| 10,197,107 |
|
Total liabilities and stockholders' equity |
| $ | 40,413,042 |
|
| $ | 40,822,161 |
|
SOURCE: Ainos, Inc.
View source version on accesswire.com:
カリフォルニア州サンディエゴ/ACCESSWIRE/2022年8月15日/
$Ainos(AIMD.US)$Ainosは多元化された医療科学技術会社で、新型の看護点検査、低用量インターフェロン療法、合成RNA駆動の予防性薬物の開発に専念している。同社は今日、2022年6月30日までの第2四半期の監査を受けていない財務業績を発表した。
2022年第2四半期の財務ハイライト
エノス董事局主席兼最高経営責任者の蔡俊賢氏は、“我々はナスダック上場会社の初の四半期業績として、前年同期より著しく増加し、各運営マイルストーンを実現することが期待できると発表した。これは私たち、私たちのパートナー、そして私たちの株主にとって重要な年だ。我々の新冠肺炎抗原自己検出は台湾での販売が許可され,われわれのVELDONAインターフェロン製剤の臨床前研究結果が陽性であり,我々の製品組み合わせの実力を示しており,我々の使命を果たし,精密医学のための遠隔医療を支援する未来を開発しようと努力しているからである。ナスダックの台頭は私たちの発展のエキサイティングな新しい章を開き、私たちにより広範な資金ルートを提供し、私たちの企業イメージを向上させ、そして私たちを株主により大きく、より持続可能な価値を提供することに位置づけた。私たちの低コスト運営と先端技術によって、私たちは多様な医療科学技術会社の未来成長の礎としてしっかりと配置されている“と述べた
エノス首席財務官の呉慧蘭氏は、“第2四半期、私たちのCOVID-19抗原迅速検出キットの販売量が増加し、営業収入が前年同期比213.6%増加した。最近の台頭に伴い、追加の資本が提供され、私たちは有利な地位にあり、私たちの製品開発目標を実現し、新興市場のチャンスをつかみ、株主に長期的な成長をもたらすことができる。将来を展望して、私たちは引き続き私たちの医療機器生産ラインを商業化し、同時に私たちの革新的な製品の組み合わせを拡大し、強化していく”と述べた
2022年第2四半期の財務実績
収入.収入
収入は2021年同期の202,992ドルから2022年第2期の636,627ドルに上昇し、増加は213.6%に達し、主にAinos CoVID-19抗原迅速検出キットの台湾での製品販売増加によるものである。
収入コスト
2022年第2四半期の収入コストは318,963ドルであるが、2021年同期は69,508ドルであり、これは主にAinos COVID-19抗原迅速検出キットの関連製品販売コストの増加によるものである。
毛利
毛利益は317,664ドルで、2022年第2四半期の売上高の49.9%を占めている。
総運営費
総運営費は2021年同期の860,030ドルから2022年第2期の2,261,960ドルに上昇し,163.0%に増加し,主に研究開発費の増加によるものである.研究·開発費の増加は,会社がその製品開発計画に基づいて研究·開発に継続的に投資していることを反映している。
純損失
2022年第2四半期の普通株主の純損失は1,954,032ドルであるべきであるが,2021年同期は749,774ドルである。
貸借対照表
2022年6月30日現在の会社の現金および現金等価物は1,753,877ドルであるのに対し,2021年12月31日現在の現金および現金等価物は1,751,499ドルである。
最新の発展動向
2022年6月21日、同社は台湾食品薬品監督管理局が2022年6月13日に台湾炭素ナノテクノロジー会社に発行した緊急使用許可に基づき、Ainos新冠肺炎抗原自己検査キットの販売を開始したと発表した。台湾炭素ナノテクノロジー会社はAinos共同テストのメーカーと製品共同開発業者である。エノスは新冠肺炎抗原自己検査キットの独占販売総代理である。
2022年6月27日、同社はその新冠肺炎のハムスターに対する抗ウイルス治療効果の研究結果を発表した。現在の結果により、その低用量インターフェロンα製剤VELDONAの経口投与は免疫反応を調節することにより、SARS-CoV-2ウイルスに感染した肺部に対して保護作用があり、それによって感染動物の回復を加速する。同社は米国FDA第2/3期臨床試験の申請書類を準備している。
2022年8月12日、会社はこれまで発表されていた78万単位のパッケージ公開を終了することを発表し、公開発行価格は単位あたり4.25ドル。今回発行された各単位は1株の普通株と1株の株式承認証を含み、4.25ドルの使用価格で普通株を購入する。普通株式と引受権証は直ちに分離され、単独で発行されることができる。この普通株と権利証は2022年8月9日にナスダック資本市場で取引を開始し、コードはそれぞれAIMDとAIMDWである。引受割引と手数料及びその他の推定発行費用を差し引く前に、Ainosは約330万ドルの毛収入を得た。
Ainos社について
カリフォルニア州サンディエゴに本社を置くAinos,Inc.(フランス/フランス/a Amarillo生物科学社)多様な医療科学技術会社であり、革新的な医療技術の開発に力を入れ、看護点検査と各種疾病適応に対する安全と斬新な医療治療に用いられている。Ainosは,低用量非注射インターフェロンを用いた特許療法に加え,医療機器と消費者保健製品を網羅した包括的ヘルスケア業務の組み合わせの開発に取り組んでいる。医療機器の商業化をその多元化戦略の一部とするとともに,Ainosは揮発性有機化合物(VOC)や新冠肺炎POCTを含む製品組合せを拡大している。VOC技術に関する特許と3つの発行された新冠肺炎POCT製品特許を利用して,同社はその医療機器生産ラインの商業化を加速させることを求めており,まずAinosブランドの新冠肺炎POCT候補製品である。
前向きに陳述する
本プレスリリースには、1995年の米国個人証券訴訟改革法安全港条項に適合する“前向き陳述”が含まれている。前向きな陳述は、“予想”、“信じる”、“推定”、“予想”、“予定”、“計画”、“予測”、“プロジェクト”、“目標”、“未来を求める”、“可能”、“戦略”、“可能”、“可能”、“すべき”、“会議する”、および将来の時期の同様の提案によって識別することができる。展望的な陳述はただ私たちの現在の信念、期待、そして仮定に基づいている。前向き陳述は固有の不確実性,リスク,環境変化の影響を受け,これらの不確実性,リスク,変化は予測が困難であり,その多くは我々が制御できないものである。私たちの実際の結果は展望的な陳述で指摘されたものと大きく違うかもしれない。
本プレスリリースで発表された計画薬物治療の生産コストと販売潜在力;米国食品医薬品局(FDA)または他の規制機関が計画薬物治療の最終承認に与える影響は、本プレスリリースで発表された計画薬物治療の生産コストと販売潜在力を含むが、これらに限定されないが、我々の実際の結果と展望性陳述に示された結果と大きく異なる重要な要素は、緊急使用許可の利用可能性を含む、会社の限られた現金および歴史的損失、会社の利益を達成する能力、企業業界の激しい競争と急速な進歩の技術は、その技術を超える可能性がある。企業が開発した製品およびサービスに対する顧客の需要;競争的または代替製品、技術および価格設定の影響;会社が開発した任意の製品を生産する能力;全体的な経済状況および事件およびそれが会社およびその潜在的な顧客に与える可能性のある影響は、“新冠肺炎”の影響を含むが、これらに限定されない;会社が将来十分な資金を得る能力;世界保健機関、食品·薬物管理局およびその他の機能は、食品·薬物管理局の政府機関が会社の業務および技術に与える法規の影響と類似している。第三者の訴訟及びその他のクレーム又は管理会社が運営する各種規制機関の調査、会社がその製品が規制部門の承認を得る能力を確保すること、及び上記項目に係るリスクを管理することに成功した。読者はまた、2021年12月31日までのForm 10-K年度報告書と、米国証券取引委員会に提出された他の報告書に記載されているリスクおよび不確実性を調べなければならない。
私たちがこのプレスリリースでした任意の展望的声明は、その声明が発表された日に限定される。私たちは時々行われる可能性のあるいかなる前向きな陳述も、書面でも口頭でも、新しい情報、未来の発展、他の状況を公開更新する義務はない。
投資家関係連絡先
ICR、LLC
楊彦宏
電話番号:+1646-224-6971
電子メール:Ainos.IR@icrinc.com
Ainos社は
簡明統合 運営説明書
(未監査)
|
| 6月30日までの3ヶ月間 |
|
| 6月30日までの6ヶ月間 |
|
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
|
収入.収入 |
| $ | 636,627 |
|
| $ | 202,992 |
|
| $ | 723,828 |
|
| $ | 205,113 |
|
収入コスト |
|
| (318,963 | ) |
|
| (69,508 | ) |
|
| (360,042 | ) |
|
| (70,757 | ) |
毛利 |
|
| 317,664 |
|
|
| 133,484 |
|
|
| 363,786 |
|
|
| 134,356 |
|
運営費 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
研究開発費 |
|
| 1,634,856 |
|
|
| - |
|
|
| 3,212,310 |
|
|
| - |
|
販売、一般、行政費用 |
|
| 627,104 |
|
|
| 860,030 |
|
|
| 1,178,834 |
|
|
| 1,383,011 |
|
総運営費 |
|
| 2,261,960 |
|
|
| 860,030 |
|
|
| 4,391,144 |
|
|
| 1,383,011 |
|
営業損失 |
|
| (1,944,296 | ) |
|
| (726,546 | ) |
|
| (4,027,358 | ) |
|
| (1,248,655 | ) |
営業外収入と費用、純額 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
固定資産販売損失 |
|
| - |
|
|
| (2,247 | ) |
|
| - |
|
|
| (2,247 | ) |
利子支出,純額 |
|
| (18,796 | ) |
|
| (20,981 | ) |
|
| (35,483 | ) |
|
| (32,879 | ) |
その他の収入、純額 |
|
| 9,060 |
|
|
| - |
|
|
| 8,914 |
|
|
| - |
|
営業外収支合計 |
|
| (9,736 | ) |
|
| (23,228 | ) |
|
| (26,569 | ) |
|
| (35,126 | ) |
純損失 |
|
| (1,954,032 | ) |
|
| (749,774 | ) |
|
| (4,053,927 | ) |
|
| (1,283,781 | ) |
普通株主は1株当たり基本と希釈して1株当たり純損失 |
| $ | (0.01 | ) |
| $ | (0.01 | ) |
| $ | (0.03 | ) |
| $ | (0.02 | ) |
加重平均発行済み普通株式-基本普通株式と希釈普通株 |
|
| 144,379,308 |
|
|
| 124,644,759 |
|
|
| 144,379,308 |
|
|
| 83,583,583 |
|
Ainos社は
簡明総合貸借対照表
(未監査)
| 六月三十日 |
|
| 十二月三十一日 |
|
| 2022 |
|
| 2021 |
|
資産 |
|
|
|
|
|
|
流動資産: |
|
|
|
|
|
|
現金と現金等価物 |
| $ | 1,753,877 |
|
| $ | 1,751,499 |
|
在庫品 |
|
| 670,507 |
|
|
| - |
|
その他流動資産 |
|
| 1,274,512 |
|
|
| 466,198 |
|
流動資産総額 |
|
| 3,698,896 |
|
|
| 2,217,697 |
|
無形資産、純額 |
|
| 35,086,424 |
|
|
| 37,329,191 |
|
財産と設備、純額 |
|
| 1,503,025 |
|
|
| 1,187,702 |
|
その他の資産 |
|
| 124,697 |
|
|
| 87,571 |
|
総資産 |
| $ | 40,413,042 |
|
| $ | 40,822,161 |
|
負債と株主権益 |
|
|
|
|
|
|
|
|
流動負債: |
|
|
|
|
|
|
|
|
転換支払手形 |
| $ | 3,376,526 |
|
| $ | 3,376,526 |
|
支払手形 |
|
| 1,013,405 |
|
|
| 213,405 |
|
費用とその他の流動負債を計算しなければならない |
|
| 2,598,468 |
|
|
| 1,004,868 |
|
支払関連先 |
|
| - |
|
|
| 26,000,000 |
|
流動負債総額 |
|
| 6,988,399 |
|
|
| 30,594,799 |
|
長期負債: |
|
|
|
|
|
|
|
|
変換可能な支払手形-非流動手形 |
|
| 27,400,000 |
|
|
| - |
|
レンタル負債を経営しています--非流動負債 |
|
| 18,323 |
|
|
| 30,255 |
|
長期負債総額 |
|
| 27,418,323 |
|
|
| 30,255 |
|
総負債 |
|
| 34,406,722 |
|
|
| 30,625,054 |
|
株主権益 |
|
|
|
|
|
|
|
|
優先株,額面0.01ドル |
|
|
|
|
|
|
|
|
許可されている |
|
|
|
|
|
|
|
|
普通株、額面0.01ドル;300,000,000株 |
|
|
|
|
|
|
|
|
2022年6月30日と12月31日から許可されている |
|
|
|
|
|
|
|
|
2021年;発行および発行済み144,379,308株 |
|
|
|
|
|
|
|
|
2022年6月30日と2021年12月31日 |
|
| 1,443,793 |
|
|
| 1,443,793 |
|
追加実収資本 |
|
| 18,943,316 |
|
|
| 18,856,430 |
|
赤字を累計する |
|
| (14,162,843 | ) |
|
| (10,108,916 | ) |
翻訳調整 |
|
| (217,946 | ) |
|
| 5,800 |
|
株主権益総額 |
|
| 6,006,320 |
|
|
| 10,197,107 |
|
総負債と株主権益 |
| $ | 40,413,042 |
|
| $ | 40,822,161 |
|
資料源:Ainos社は
Accesswire.comでソースコードバージョンを表示する: